BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Steven C. Quay, M.D., Ph.D., of Atossa Genetics, Inc. Elected as a Fellow of the College of American Pathologists


3/14/2011 8:26:24 AM

SEATTLE, WA--(Marketwire - March 14, 2011) -

Atossa Genetics, Inc., a privately-held health care company focused on the development and marketing of novel cellular and molecular diagnostic risk assessment products for breast cancer, announced today that Steven C. Quay, M.D., Ph.D., Chairman, President and CEO, has been elected as a Fellow of the College of American Pathologists (FCAP).

The College of American Pathologists (CAP) is the leading organization of board-certified pathologists, serving approximately 17,000 physician members and the laboratory community to foster and advocate for excellence in the practice of pathology and laboratory medicine.

"I am honored to have been elected as a Fellow of the College of American Pathologists, a world-renowned medical society known for its industry leadership in laboratory quality assurance and strong advocacy for high-quality, cost-effective medical care," commented Dr. Quay. "I look forward to working with the CAP to advance the interests of the pathology community and patients."

About Steven C. Quay, M.D., Ph.D.

Dr. Quay is Chairman, President and CEO of Atossa Genetics, Inc., a privately held health care company that has developed and is commercializing the Mammary Aspirate Specimen Cytology Test System (MASCT System), a new, patented, FDA-cleared breast cancer risk assessment test. Dr. Quay is a named inventor on 14 U.S. and foreign patents covering the MASCT System.

A physician, scientist, and biotechnology entrepreneur, Dr. Quay has founded six companies and rebranded a seventh during a more than 25-year career. He has invented five drugs, as well as the MASCT System, which have been approved by the FDA, and has received 69 U.S. patents.

He is certified in Anatomic Pathology with the American Board of Pathology, is a Fellow of the College of American Pathologists, and is a member of the American Society of Investigative Pathology, the Association of Molecular Pathology, the Society for Laboratory Automation and Screening, and the Association of Pathology Informatics.

Dr. Quay completed an internship and residency in anatomic pathology at the Massachusetts General Hospital, a Harvard Medical School teaching hospital. He is a former faculty member of the Department of Pathology, Stanford University School of Medicine.

Dr. Quay has received a number of prestigious awards over the course of his career including Ernst & Young's 1997 Entrepreneur of the Year. In February 2011, he was recognized by Seattle Business magazine as one of the top healthcare leaders in the Pacific Northwest.

About the Mammary Aspirate Specimen Cytology Test System

The MASCT System, a "Pap test for breast cancer," is designed to collect nipple aspirate fluid (NAF), which contains cells from the lining of the milk ducts and the lobules where approximately 85% of all breast cancers originate. Once collected, the NAF sample will undergo analysis in Atossa's specially equipped pathology lab to determine whether the cells are normal, atypical (premalignant), or malignant. The MASCT System uses no radiation, is simple, painless, and inexpensive, and takes less than 5 minutes in a doctor's office or mammography center. The MASCT System is intended as an adjunct to mammography for women ages 40 to 75 and for younger women at high risk for breast cancer.

The MASCT System is expected to be launched in the Pacific Northwest this year and across the U.S. in 2012.

About Atossa Genetics, Inc.

Atossa Genetics, Inc. is a privately held health care company dedicated to improving breast health by commercializing the Mammary Aspirate Specimen Cytology Test System (MASCT System and second-generation products in development. Patients, health care providers, investors and others seeking information on the MASCT System or the latest information and research on breast cancer risk assessment, diagnostics, prevention, and treatment options, should visit www.atossagenetics.com.


Contacts:

Corporate:

Steven C. Quay, M.D., Ph.D.
Chairman, President and CEO
206-325-6086
Email Contact

Investors and Media:

Matthew D. Haines
Managing Director
MBS Value Partners
212-710-9686
Email Contact

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES